

Short Communication

Potential Transfer by Refugees of Systemic Leishmaniasis into Vector Free Zones

Nuha Nuwayri-Salti*

Department of Human Morphology, American University of Beirut, Lebanon

*Corresponding author

Nuha Nuwayri-Salti, Department of Human Morphology, American University of Beirut, Chronic Care Center, Baabda, Lebanon, Tel: 961-1366-462; Email: nuhaakanoueiri@gmail.com

Submitted: 02 March 2017

Accepted: 20 May 2017

Published: 25 May 2017

ISSN: 2475-9430

Copyright

© 2017 Nuwayri-Salti

OPEN ACCESS

Abstract

The Middle East with the Mediterranean basin is a region that separates central and north Europe from Asia in the east. It represents a "buffer" zone in most aspects from the climatic, to the genetics of the living including humans, fauna and flora. Part of the peculiarities in this area is the macro and microenvironments around the humans.

INTRODUCTION

One specific feature is that this area has been since millenniums and continues to be endemic for a vector born infection leishmaniasis. This infection was noted for at least a century in both its anthroponotic and zoonotic forms, expressed clinically either as a cutaneous disease or as a systemic infection [1-3]. The Cutaneous form, in general, is a self-limiting infection that heals irrespective of whether treated or not. Still in some of these subjects (close to one third) the parasites from the skin lesion invade the blood and remain in circulation even after total healing of the skin lesion [4]. In contrast the systemic form, visceral leishmaniasis belongs to the list of "Neglected Tropical Diseases" and is considered a public health threat worldwide. It is referred to as Kala azar, which is often fatal in infants and children less than three years old and in old age (people above seventy) [5]. This parasite is propagated, in endemic zones, by the bite of several species of *Phlebotomine* sand flies which have been proven to exist in the Middle East for at least 120 million years [1,2,6]. After the sandfly bite the incubation period varies greatly. It extends from several months to more than ten years [5,7]. According to WHO report (2016) an estimated 900,000–1.3 million new cases and 20,000 to 30,000 deaths occur annually" [8]. Apparently this infection is spreading, although the report mentions that "only a small fraction of those infected by *Leishmania* parasites will develop the disease". The rest of infected subjects (who resist clinical manifestations) represent a reservoir for these organisms. Over the past few decades, reports of patients with Kala azar in non-endemic zones have been increasing. Such are due to either activation of the latent infection; secondary to sudden increased stress on the immune system, or that these carriers transmitted the organism to subjects with reduced immunity. This happens independent of the presence of vectors. Furthermore blood and its products from any of the above "carriers" may transmit the parasite, as happens in newborns and in patients who receive other organ transplants

[9-12]. Leishmania is as pathogenic to many other mammals such as canines and feline animals in the Mediterranean basin [12-14] the infection develops very slowly with the clinical signs and symptoms appearing over a long stretch of time [13]. This reservoir for the parasite existed strictly in endemic zones although more recently it seems to be increasing in number in non-endemic regions [13]. The implications of all of the above reports, on public health are very serious not only in endemic regions but also in non-endemic areas.

DISCUSSION

As already mentioned, we chose leishmaniasis, a parasitic infection, to illustrate our objective. The disease was first described in 1902 in India by a British medical officer C. Donovan [15]. Then this was followed by mapping around the globe, all the regions where this infection existed. The presence of the infection with this parasites was organically bound with the presence of the sand fly vector and the presence of the reservoir animal mainly canines. However, in the past three decades, reports of kala azar in vector free areas started to be published and attracted a great deal of attention [5]. It was reported that not everyone who harbors this parasite develops the clinically described systemic leishmaniasis with its classical symptoms. Some patients may present with much milder symptoms depending on the integrity of the immune system and on, probably, the size of the inoculum when bitten by the infected sand fly. Such patients may present with non-specific symptoms, or remain unidentified with no symptoms at all. They are the larger proportion of the *Leishmania* parasite infected population and are now referred to as "carriers" [16]. Displacement of any group, of *Leishmania* carriers into regions non-endemic for leishmania parasites makes out of such populations a time bomb. They can transmit the parasite by donating any organ including blood [16-26] (Figure 1,2) their body fluids carry the parasites, thus making the human carrier the center of a focus that can propagate unknowingly the infection




Figure 1 Skin window, slide 2 (16hrs) on a patient, revealing a motile monocyte (star near pseudopodia) with doublets of amastigotes in the cytoplasm around and over the nucleus (arrow) cytoplasm expanded, thin and vacuolated (crescent). Modified Romanovsky stain: Wright Giemsa. Oil immersion lens (magnification 100x).




Figure 2 Skin window, slide 2 (16hrs) on a patient, revealing a motile monocyte (pseudopodia) with clusters of amastigotes in the cytoplasm around and over the nucleus. Cytoplasm expanded. Cell is stained with hyper immune antileishmania antibody visualized by fluorescinated goat anti rabbit antiserum. Oil immersion lens (magnification 100x).

in the new environment [21]. Unfortunately most tests available rely on the presence of a positive immune reaction to *Leishmania* antigens, yet unfortunately this does not indicate whether the parasite is still present in the subject or not. A better test is the use of Skin Window" [16] which aggregates pure agranulocytes on a slide in a high enough number to examine scores of cells for the presence of amastigotes. If inconclusive we can use indirect immunofluorescence tagged antibodies (sandwich technique) to detect the parasite. Certainly PCR can be used but all it reveals is DNA of the parasite in the carrier blood and again this is no proof whether the intact parasite is there or not unless it is used on scrapings from Skin Window. Furthermore the cost of PCR makes it available on a very limited scale, and not on waves of refugees.

CONCLUSION

To conclude we have witnessed over the last few decades,

the remarkable increase in mobility of subjects among countries and even among continents such as from Africa, and the Middle East to Europe, and even more to Europe (central and northern), in addition to north America. More recently, we have been observing exodus of much larger groups of people from one geographic zone to another, with sometimes almost insignificant control. The objectives of this short review is to express concern on the potential hazard of a rapid spread of infections resulting from large scale migrations of peoples from endemic to non-endemic regions.

REFERENCES

1. Desjeux P. Information on the Epidemiology and control of the *Leishmaniasis* by country or territory. Geneva, World Health Organization. 1991; 30,16,18, & 29
2. Neoumi N. *Leishmaniasis* in the Eastern Mediterranean region. Eastern Mediterranean Health Journal. 1996; 2: 94-101.
3. Fenech FF. *Leishmaniasis* in Malta and the Mediterranean basin. Ann Trop Med Parasitol. 1997; 91: 747-753.
4. Nakkash-Chmairie H, Makki R, Nahhas G, Knio K, Nuwayri-Salti N. Detection of *Leishmania* parasites in the blood of patients with isolated cutaneous *leishmaniasis*. Int J Infect Dis. 2011; 15: e491-494.
5. Gramiccia M, Scalone A, Di Muccio T, Orsini S, Fiorentino E, Gradoni L. The burden of visceral *leishmaniasis* in Italy from 1982 to 2012: a retrospective analysis of the multi-annual epidemic that occurred from 1989 TO 2009. Euro Surveill. 2013; 18: 20535.
6. Lerner EA, Iuga AO, Reddy VB. Maxadilan, a PAC1 receptor agonist from sand flies. Peptides. 2007; 26: 1651-1654.
7. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of *Leishmania major* infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol. 2000; 165: 969-977.
8. WHO factsheet on *Leishmania*, 2016.
9. Chung HL, Chow KK, Lu JP. The first two cases of transfusion kala-azar. J Chin Med. 1948; 66: 325-326.
10. Kostman R, Barr M, Bengtsson E, Garnham EPCC, Hult G. Kala-azar transferred by exchange blood transfusion in two Swedish infants, p. 384. In, Proceedings of the Seventh International Congress of Tropical Medicine and Malaria. World Health Organization, Geneva, Switzerland. 1963.
11. Palatnik-de-Sousa CB, Paraguai-de-Souza E, Gomes EM, Soares-Machado FC, Luz KG, Borojevic R. Transmission of visceral *leishmaniasis* by blood transfusion in hamsters. Braz J Med Biol Res. 1996; 29: 1311-1315.
12. Gramiccia M, Scalone A, Di Muccio T, Orsini S, Fiorentino E, Gradoni I. The burden of visceral *leishmaniasis* in Italy from 1982 to 2012: a retrospective analysis of the multi-annual epidemic that occurred from 1989 to 2009. Eurosurveillance. 2013; 18.
13. Dantas-Torres F. The role of dogs as reservoirs of *Leishmania* parasites, with emphasis on *Leishmania (Leishmania) infantum* and *Leishmania (Viannia) braziliensis*. Vet Parasitol. 2007; 149: 139-146.
14. The Center for Food Security & Public Health. Iowa State University College of Veterinary Medicine. Institute for International Cooperation in International Cooperation in Animal Biologics. *Leishmaniasis* (Cutaneous and Visceral) Kala-azar, Black Fever, Dumdum Fever, Oriental Sore, Tropical Sore, Uta, Chiclero Ulcer, Aleppo Boi, Pian Bois; Espundia Last Updated: 2009.
15. Donovan C. The etiology of one of the hetero geneous fevers of india.

- Br Med J. 1903; 2: 1401.
16. Rebeck JW, Cromley JH. A method of studying leukocytic functions in vivo. *Ann N Y Acad Sci.* 1955; 59: 757-805.
17. Nuwayri-Salti N, Khansa HF. Direct non-insect vector transmission of *Leishmania* parasites in mice. *Int J Parasitol.* 1985; 15: 497-500.
18. Mauny I, Blanchot I, Degeilh B, Dabadie A, Guiguen C, Roussey M. Leishmaniose viscérale chez un nourisson en Bretagne: discussion sur les modes de transmission hors de zones endémiques. *Pediatric.* 1993; 48: 237-239.
19. Viana GMC, Nascimento MDSB, Viana MGC, Burattini MM. Congenital transmission of Kala-Azar. *Rev Soc Bras Med Trop.* 2001; 34: 247.
20. Nuwayri-Salti N, Fallah Khansa H. Direct non-insect-vector transmission of visceral *leishmaniasis* (Kala-Azar). from an asymptomatic mother to her child. *Pediatrics.* 1999; 104: e65.
21. Basset D, Faraut F, Marty P, Dereure J, Rosenthal E, Mary C, et al. Visceral *leishmaniasis* in organ transplant recipients: 11 new cases and a review of the literature. *Microb Infect.* 2005; 7: 1370-1375.
22. Berenguer J, Gómez-Campderá F, Padilla B, Rodríguez-Ferrero M, Anaya F, Moreno S, et al. Visceral *leishmaniasis* (Kala-Azar) in transplant recipients: case report and review. *Transplantation.* 1998; 65: 1401-1404.
23. Hernández-Pérez J, Yebra-Bango M, Jiménez-Martínez E, Sanz-Moreno C, Cuervas-Mons V, Alonso Pulpón L, et al. Visceral *leishmaniasis* (Kala-azar) in solid organ transplantation: report of five cases and review. *Clin Infect Dis.* 1999; 29: 918-921.
24. Cohen C, Corazza F, De Mol P, Brasseur D. *Leishmaniasis* acquired in Belgium. *Lancet.* 1991; 338: 128.
25. The Center for Food Security & Public Health. Iowa State University College of Veterinary Medicine. Institute for International Cooperation in International Cooperation in Animal Biologics. *Leishmaniasis* (Cutaneous and Visceral) Kala-azar, Black Fever, Dumdum Fever, Oriental Sore, Tropical Sore, Uta, Chiclero Ulcer, Aleppo Boi, Pian Bois; Espundia Last Updated: October 2009. Iowa State University, College of Veterinary Medicine.
26. Giger U, Oakley DA, Owens SD, Schantz P. *Leishmania donovani* transmission by packed RBC transfusion to anemic dogs in the United States. *Transfusion.* 2002; 42: 381-382.

Cite this article

Nuwayri-Salti N (2017) Potential Transfer by Refugees of Systemic Leishmaniasis into Vector Free Zones. *Ann Clin Cytol Pathol* 3(4): 1063.